anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An electronic medical records (EMR) system that enables a user to import paper-based clinical form templates (typically Word documents) and insert data tags in the data fields on the templates. This approach allows the user to retrieve clinical data from user inputs and from hospital recordkeeping systems, such as HIS, LIS, RIS/PACS, and others to generate EMR forms. Medical personnel can then access the data to generate descriptive, predictive, or prescriptive analytics including vital sign charts, drug interaction warnings, and drug recommendations. The system also enables secure data sharing between healthcare facilities using a blockchain system or a FHIR server. Upon signing an EMR form with one or more electronic signatures, the system generates a digitized image including images of the electronic signatures. The system generates hash of the digitized image and store the hash to the blockchain system, wherein the hash is used to verify the signed EMR form.
An isolated polypeptide inhibitor of SuIfIa having a sequence which is a variant of Sulf1a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of SuIf1a may be the alternatively spliced isoform SuIf1b. An isolated polypeptide inhibitor of Sulf2a having a sequence which is a variant of Sulf2a, and which lacks sulfatase activity and lacks the ability to bind to the surface of a cell. The polypeptide inhibitor of Sulf2a may be the alternatively spliced isoform Sulf2b. A method of combating a cancer in which Wnt signalling is upregulated or of treating ischaemia in a patient, the method comprising administering to the patient a polypeptide inhibitor of Sulf1a and/or Sulf2a. A method of combating a cancer in which Wnt signalling is not upregulated, the method comprising administering to the patient an inhibitor of Sulf1b and/or Sulf2b.
Patients undergo acupuncture therapy and receive BCG via intravesical injection on days 1, 8, 15, 22, 29, and 36 in the absence of unacceptable toxicity. Patients also receive standard of care symptom management.
BACKGROUND: A lack of brain expansion is considered a risk factor for recurrence after evacuation of a chronic subdural hematoma (CSDH). To the best of our knowledge, no studies have reported on objective measurement of brain expansion after evacuation of a CSDH.
METHODS: We performed a retrospective analysis of prospectively collected data of patients undergoing 2 burr hole evacuation of a CSDH. We measured the depth of the brain surface from the frontal burr hole dural opening after hematoma evacuation using a specially devised measuring tool. Other predictors analyzed for recurrence of hematoma were age, gender, a history of hypertension, the use of anticoagulant and/or antiplatelet agents, Glasgow coma scale score at presentation, unilateral or bilateral hematoma, computed tomography appearance, and hematoma thickness.
RESULTS: Among 88 patients who underwent hematoma evacuation, 3 (3.4%) underwent surgery for recurrence. The significant factors associated with recurrence were the presence of bilateral hematoma (P = 0.001), hematoma width >2.3 cm (P = 0.04), gradation type of hematoma on the computed tomography scan (P = 0.03), and the depth of the brain after hematoma evacuation (P = 0.02). The brain expanded less in those with recurrence, with a mean depth of the brain of 18 ± 6 mm versus 7.27 ± 7.8 mm in those without recurrence.
CONCLUSIONS: Evacuation of a CSDH through 2 burr holes, along with copious irrigation and bed rest for 3 days, resulted in a very low recurrence rate without the use of a drain. A lack of brain expansion might be a predictor of recurrence. To the best of our knowledge, this is the first study to quantitatively measure the depth of the brain at surgery in patients undergoing surgery for CSDH.
Patients receive axitinib PO BID. Courses repeat every 4 weeks in the absence of disease progression or unacceptable toxicity.
BACKGROUND: The prevalence of neuropathic pain (NP) in burn patients is reported in the literature to be as high as 80%1. Given the complexity of NP in burn patients and the wide range of treatments available, a systematic review of the literature is warranted to summarize our current understanding of management and treatment of NP in this population.
METHODS: This systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines. The following databases were queried to identify relevant articles: PubMed, Cochrane, Embase, Scopus, Ovid, and Web of Science. The main outcome measures were incidence and management of NP. Secondary outcomes included risk factors for NP.
RESULTS: Included articles presented findings from 11 different countries, capturing outcomes for 4366 patients. Risk factors for neuropathic pain in burn patients were identified, including older age, alcohol and substance abuse, current daily smoking, greater % total body surface area burns (TBSA), and longer hospitalizations. Pharmacologic treatments included gabapentin/pregabalin (n = 7), ascorbic acid (n = 1), and lidocaine (n = 1). Overall, the studies showed varied results regarding the efficacy of pharmacological treatments. While certain studies demonstrated gabapentanoids to be effective in reducing neuropathic symptoms, others found conflicting results. With regards to non-pharmacologic treatments, electroconvulsive therapy (n = 1), electropuncture (n = 1), nerve release/reconstruction (n = 2), and somatosensory feedback rehabilitation (n = 1) were used and demonstrated promise in reducing pain intensity and improving functionality.
CONCLUSIONS: Despite NP afflicting the majority of burn patients long after their injury, this systematic review demonstrates insufficient evidence on the pathophysiology, outcomes, and risk factors in NP, as well as the efficacy of various therapies. Future prospective and randomized studies evaluating the etiology of these factors can substantially improve our treatment strategies. This can allow for the development of well-delineated and evidence-based protocols in NP management in hopes of improving quality of life and both psychological and physical function in burn patients.
PROBLEM TO BE SOLVED: To obtain the subject composition capable of improving internal absorption of a medicament while keeping the chemical stability of the medicament, and useful for improvement of bioavailability by including the specific medicament, a water-soluble polymer and an acid. SOLUTION: This composition comprises a medicament of the formula, a water-soluble polymer (e.g. hydroxypropylmethylcellulose) and an acid. The weight ratio of the water-soluble polymer to the medicament is 1-10, and the weight ratio of the acid is 0.1-10, preferably 0.1-1. The acid to be used is preferably an organic acid, and especially citric acid is most preferable. An ordinarily used additive (e.g. a corrigent) can be formulated therewith. The solid dispersing element is obtained by dissolving the medicament of the formula, the water-soluble polymer and the acid in a solvent (e.g. a mixed solution of water and ethanol), and distilling off the solvent therefrom.  The solid preparation having internal absorption and chemical stability of the medicament of the formula can be obtained by adding the acid to the solid dispersing element comprising the medicament of the formula and the water-soluble polymer.
Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF-blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and requiring treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation.
Six dose levels will be tested. The dose-limiting toxicity (DLT) will be assessed from the first administration of SYHA1815 to the end of the first cycle (28 days).
PCT No. PCT/GB93/01350 Sec. 371 Date Nov. 22, 1994 Sec. 102(e) Date Nov. 22, 1994 PCT Filed Jun. 28, 1993 PCT Pub. No. WO94/00164 PCT Pub. Date Jan. 6, 1994An alginate fibre is provided which includes one or more medicaments incorporated into the fibre core such that the one or more medicaments can be released in a sustained manner over time and, optionally, one or more medicaments attached to the surface of the fibre whereby the one or more medicaments attached to the surface of the fibre can be released rapidly therefrom.
<P>PROBLEM TO BE SOLVED: To provide a production method of sesame and green wheat granules capable of obtaining a food material excellent in taste, storage stability and beautiful skin effect by combining green leaves of wheats and sesame.  <P>SOLUTION: A dry powder of green leaves of wheats, sesame and food fibers are mixed in a proper ratio to produce a sesame and green wheat compound and this compound is molded into granular shape. In the mixing process, the dry powder of green leaves of wheats and sesame are set to a weight ratio of 5 : 1 to 1 : 2 and sesame is mixed so that sesame becomes at most 30 wt.% in sesame and green wheat granules. In this case, the mixing process includes a process for mixing a vehicle. Further, green leaves of wheats are young leaves of barley.  <P>COPYRIGHT: (C)2004,JPO
OBJECTIVES: Building upon our recently developed conceptual definition of oral frailty (the age-related functional decline of orofacial structures), this e-Delphi study aims to develop an operational definition of oral frailty by identifying its components.
METHODS: We used a modified e-Delphi study to reach a consensus among international experts on the components of oral frailty. Twelve out of fifteen invited experts in the field of gerodontology participated. Experts responded to three rounds of an online 5-point scale questionnaire of components to be included or excluded from the operational definition of oral frailty. After each round, scores and rationales were shared with all experts, after which they could revise their position. A consensus was reached when at least 70% of the experts agreed on whether or not a component should be included in the operational definition of oral frailty.
RESULTS: The experts achieved a high level of agreement (80 - 100%) on including eight components of oral frailty and excluding nineteen. The operational definition of oral frailty should include the following components: 1) difficulty eating hard or tough foods, 2) inability to chew all types of foods, 3) decreased ability to swallow solid foods, 4) decreased ability to swallow liquids, 5) overall poor swallowing function, 6) impaired tongue movement, 7) speech or phonatory disorders, and 8) hyposalivation or xerostomia.
CONCLUSION: This e-Delphi study provided eight components that make up the operational definition of oral frailty. These components are the foundation for the next stage, which involves developing an oral frailty assessment tool.
The present invention relates to the use of peroxometallic compounds, such peroxovanadium compounds, to prevent angiogenesis, restenosis and the production of endothelins, as immunomodulators and as antitumorigenic agents. Peroxometallic compounds are preferred since they are more potent, and less toxic, than their "oxo" counterparts, as exemplified by specific peroxovanadium compounds. Anti-angiogenic activity was verified in vitro against human umbilical vascular endothelial cells (HUVECs) as well as ex ovo using the chicken chorioallantoic assay membrane and in the rat aortic ring model and a Matrigel assay in vivo. Peroxovanadium compounds also decrease basal levels and inhibit the increase in plasma endothelins occurring following insulin induction in rats. It is proposed that peroxovanadium compounds are therapeutically-active anti-angiogenics and useful in preventing vascular restenosis by acting, inter alia, by inhibiting one or several protein tyrosine phosphatases (PTPs) involved in the proliferation, differentiation and migration of cells or the secretion of peptides (such endothelins and immunomodulators), or both. These compounds have also been found to be suitable as antitumorigenic agents in the treatment of cancer, such as breast cancer and prostate cancer.
This is an enhanced behavioral intervention. Mentor Mothers trained with a standard study curriculum are assigned to pregnant HIV-positive women accessing care at Primary Healthcare Centers in study communities. Under close daily supervision, Mentor Mothers provide support and counseling for the mother-infant pairs until the exposed infant is 12 months old. Study participants in this arm also receive standard of care PMTCT services.
INTRODUCTION: Squamous cell carcinoma of unknown primary in the head and neck (HNSCCUP) remains a diagnostic challenge. Tongue base mucosectomy by transoral robotic surgery (TORS-TBM) can increase the diagnostic yield and de-intensify treatment. However, the added value of TORS-TBM as an adjunct to work-up programs for HNSCCUP is unclear. Furthermore, the optimal extent of the procedure and selection criteria remain to be established.
AIM: The primary aim of the present study was to assess the diagnostic yield of TORS-TBM as a supplement to a standardized work-up program, using the Danish national guidelines as an example. Secondary aims include predictive values of HPV-testing and PET/CT.
METHODS: This was a national multicenter observational cohort study including all patients diagnosed with HNSCCUP from January 2013 to December 2019, who subsequently underwent TORS-TBM. In most cases HPV status was based on dual testing (p16 and HPV-DNA). Predictive values of PET/CT and HPV status were calculated.
RESULTS: A total of 100 consecutive patients underwent TORS-TBM; 93 total TBMs and 7 unilateral TBMs. The primary tumor was detected in 49 % (49/100) of patients. The detection rate was 58 % (47/81) in patients with HPV-associated disease (PPV of HPV status) and 11 % (2/19) in patients with HPV-independent disease. The NPV of HPV status was 89 %. The PPV and NPV of PET/CT was 53 % and 52 %, respectively.
CONCLUSION: Adding total TORS-TBM to the current Danish guideline-based work-up program on HNCCCUP patients with HPV-associated disease significantly improved the diagnostic yield.
Subjects randomized to usual care will receive medical oncology, radiation oncology, pulmonary, CT surgery as indicated by the type of cancer. At the completion of 3 months of usual care, subjects are invited to join the intervention arm.
Preconditioning will be performed in the same manner as several previous trials. Immediately after induction of anaesthesia, a standard, CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure \>185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
GOALS: Assess the outcomes of various therapeutic regimens to treat initial endoscopic postoperative recurrence despite biologic prophylaxis.
BACKGROUND: Postoperative biologic prophylaxis reduces postoperative Crohn's disease (CD) recurrence rates. Optimal treatment strategies for endoscopic recurrence have not been elucidated.
STUDY: Retrospective cohort study of adult CD patients who underwent ileocolonic resection between 2009 and 2020. Patients with endoscopic postoperative recurrence despite prophylactic biologic therapy and ≥1 subsequent colonoscopy were included. Treatment changes after recurrence were categorized as (1) therapy optimization or continuation or (2) new biologic class. The primary outcome was composite endoscopic or surgical recurrence at the time of or prior to subsequent follow-up colonoscopy.
RESULTS: Eighty-one CD patients with endoscopic recurrence (54.3% i2b, 22.2% i3, and 23.5% i4) despite biologic prophylaxis (86.4% anti-tumor necrosis factor, 8.6% vedolizumab, 4.9% ustekinumab) were included. Most patients received therapy optimization or continuation (76.3%, n=61) following recurrence compared to being started on a new biologic class. Sixty patients (N=48 therapy optimization; N=12 new biologic class) experienced composite recurrence (78.3% endoscopic, 21.7% surgical). On multivariable modeling, initiation of a new biologic class was associated with reduced risk for composite recurrence compared to therapy optimization or continuation (aOR: 0.26; P =0.04). Additionally, initiation of a new biologic class was associated with endoscopic improvement when adjusting for endoscopic severity at the time of recurrence (aOR: 3.4; P =0.05). On sensitivity analysis, a new biologic class was associated or trended with improved rates of endoscopic healing and composite recurrence when directly compared to therapy optimization or continuation.
CONCLUSION: In patients with CD who experience endoscopic recurrence despite biologic prophylaxis, changing the mechanism of biologic action may promote endoscopic improvement.
The prevalence of overactive bladder (OAB) is known to be higher in patients with type 2 diabetes (T2DM). However, few studies have examined specific risk factors contributing to its progression among diabetes mellitus (DM) patients, so this study aimed to investigate the risk factors specific to diabetes mellitus that influence overactive bladder in the Syrian population. This cross-sectional study was conducted at four endocrinology centers in four Syrian provinces: Damascus, Aleppo, Homs, Hama, and Latakia. The study was comprised of patients who had been diagnosed with both T2DM and OAB and had visited these centers from February 2020 to January 2023. The Arabic version of the Overactive Bladder Symptom Score (OABSS) scale was used to categorize the participants based on the severity score into two groups: the mild OAB group and the moderate-severe OAB group. A logistic analysis was conducted to assess the risk factors associated with the OAB among patients with diabetes. Among the 153 patients diagnosed with both DM and OAB, significant distinctions were found between the two groups concerning the severity of overactive bladder, age, duration of diabetes, symptomatic diabetic peripheral neuropathy (DPN), and ankle reflex (P < 0.05). Furthermore, a multivariate analysis revealed that age (OR 1.48, 95% CI 0.89-2.19), duration of diabetes (OR 1.94, 95% CI 0.53-2.23), and symptomatic DPN (OR 2.74, 95% CI 1.39-4.13) independently acted as risk factors for the advancement of OAB. The severity of OAB in Syrian patients with diabetes is closely associated with the severity of DM. Factors such as age, duration of diabetes, and symptomatic DPN are independent predictors of the severity of OAB. Patients who experience symptomatic DPN are at an increased risk of developing OAB.
The long term goal of the investigators work is to implement real world CPR training strategies that match training locales with at-risk populations, maximize resuscitation skill retention, and promote willingness to act. To accomplish this, the investigators will empower stakeholders at UPHS and local area hospitals to develop local implementation approaches, using either volunteers or nursing staff as training proctors. These stakeholders will be studied as a research subset. The training proctors will train family members or friends of patients at risk for cardiac arrest using either a video-only method or video self-instruction (VSI) kit, and empower them with the lifesaving skill of CPR. The investigators will use the American Heart Association's CPR Anytime VSI kit which comes equip with a DVD and inflatable manikin. For the group receiving the video-only method, the investigators will remove the inflatable manikin and train the subjects with the DVD. The investigators will randomize family members of high risk for CA to either the video-only or VSI kit method of training. The training proctors will be instructed to switch training methods every 6 months. The investigators will follow up with the study subjects and conduct CPR skills tests from 6 to 12 months from time of training to assess whether the subjects retained their skills or if they had an opportunity to use the skills that they learned. The investigators will also gather information on how the subjects would like to be encouraged to practice their skills. The investigators will send a reminder notification every two months following training, to encourage the subjects to refresh their training skills. At the follow-up skills test at 6 to 12 months, we will administer a survey to assess whether the prompting encouraged the subjects to practice their skills.
The invention discloses an application of an AIE probe for specifically recognizing Abeta protein to Alzheimer's disease, which comprises the preparation of up-conversion nanoparticles, the design of plasmids and AAV packaging plasmids, and specifically comprises the following steps: 1) preparing the upconversion nanoparticles. 2) Searching a proper NpHR gene sequence, synthesizing NpHR, and constructing a plasmid. 3) Detecting the expression of the recombinant plasmid, and detecting the NpHR. 4) The ligated plasmids were packaged with AAV and the packaging was examined. 5) And mixing the packaged AAV with the up-conversion nanoparticles, and injecting the mixture into the brain. 6) The potential change on both sides of the cell membrane was detected with patch clamp. The invention designs photosensitive protein capable of being expressed in the brain, the photosensitive protein and the up-conversion nano particles are injected into the brain together, under the irradiation of near infrared rays, the up-conversion nano particles can emit green light, the green light can excite the photosensitive protein channel to be opened, and anions can flow in, so that the excitation of neurons is inhibited, and the Parkinson is further treated.